Patent NZ-509837-A (NZ)
Title: 2-substituted-4-substitued amino-1,2,3,4-tetrahydroquinolines useful as cholesteryl ester transfer protein inhibitors
Inventor: DENINNO MICHAEL PAUL
IPC: C07D215/42
Filed: 1999-09-10
Abstract: A compound of formula (I) or a pharmaceutically acceptable salt thereof has the formula (I) wherein: R1 is Y, W-X or W-Y with X being O-Y, S-Y, N(H)-Y or N(Y)2; each Y is independently Z or an optionally saturated 1 to 10 membered carbon chain with the carbons other than the connecting carbon may be optionally replaced by one or more heteroatoms of O, S or N optionally substituted by Z and Z is an optionally saturated optionally substituted 3 to 8 membered ring having 1 to 4 heteroatoms of O, S or N or a bicyclic ring consisting of two fused optionally saturated optionally substituted 3 to 6 membered ring having 1 to 2 heteroatoms of O, S or N; R2 is an optionally saturated optionally substituted 1 to 6 membered carbon chain with the carbons other than the connecting carbon may be optionally replaced by one or two heteroatoms of O, S or N or R2 is an optionally saturated optionally substituted 3 to 7 membered ring having 1 to 2 heteroatoms of O, S or N; R3 is H or Q with Q being an optionally saturated 1 to 6 membered carbon chain with the carbons other than the connecting carbon may be optionally replaced by one heteroatom of O, S or N optionally substituted by V and V is an optionally saturated optionally substituted 3 to 8 membered ring having 1 to 4 heteroatoms of O, S or N or a bicyclic ring consisting of two fused optionally saturated optionally substituted 3 to 6 membered ring having 1 to 4 heteroatoms of O, S or N; R4 is cyano, formyl, W1Q1, W1V1, alkyleneV1 or V2 and W and W1 are independently CO, CS, SO or SO2; Q1 is an optionally saturated 1 to 6 membered carbon chain with the carbons other than the connecting carbon may be optionally replaced by one heteroatom of O, S or N optionally substituted by V1 and V1 is an optionally saturated optionally substituted 3 to 6 membered ring having 1 to 2 heteroatoms of O, S or N or a bicyclic ring consisting of two fused optionally saturated optionally substituted 3 to 6 membered ring having 1 to 2 heteroatoms of O, S or N; V2 is an optionally saturated optionally substituted 5 to 7 membered ring having 1 to 4 heteroatoms of O, S or N; provided that R3 and R4 does not include oxycarbonyl linked directly to the C4 nitrogen and either R3 must contain V or R4 must contain V1; R5 to R8 are independently H, T, nitro, halo or is an optionally saturated 1 to 12 membered carbon chain with the carbons other than the connecting carbon may be optionally replaced by one or two heteroatoms of O, S or N optionally substituted by T or R5 and R6 or R6 and R7 and/or R7 and R8 taken together form at least one optionally saturated optionally substituted 4 to 8 membered ring having 1 to 3 heteroatoms of O, S or N and T is an optionally saturated optionally substituted 3 to 12 membered ring having 1 to 4 heteroatoms of O, S or N or a bicyclic ring consisting of two fused optionally saturated optionally substituted 3 to 6 membered ring having 1 to 2 heteroatoms of O, S or N. The compounds are useful to treat atherosclerosis and cardiovascular diseases.